Sign in Subscribe

Archive

A collection of 715 issues

Latest

NCI-MATCH trial analysis compares tumor genomic alterations in adolescents and young adults versus older patients

Skip to content The CRC Digest NCI-MATCH trial analysis compares tumor genomic alterations in adolescents and young adults versus older patients Analysis of 759 colorectal cancer patients from the NCI-MATCH trial compared genomic profiles between AYAs (18-39 years, n=43) and non-AYAs (40+ years) using a 143-gene panel. (JCO Precision

Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures

Skip to content The CRC Digest ◇ RESEARCH Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures Genomic profiling has identified mutational signatures SBS88 and ID18 in colorectal tumors exposed to colibactin from pks+ E. coli, with emerging data suggesting enrichment in early-onset CRC. (Infection, Genetics and

Study identifies distinct stigma profiles among colorectal cancer patients with ostomies

Skip to content The CRC Digest ♥ LIVING WITH CRC Study identifies distinct stigma profiles among colorectal cancer patients with ostomies A cross-sectional survey of 449 patients with colorectal cancer and intestinal ostomy used latent profile analysis to identify stigma subtypes and found that stoma acceptance mediates the relationship between stigma

AI method for classifying pathology whole slide images using self-distillation technique

Skip to content The CRC Digest ◇ RESEARCH AI method for classifying pathology whole slide images using self-distillation technique Researchers developed a phenotypic self-distillation approach to classify whole slide images in colorectal cancer, addressing limitations of current attention mechanisms in Multiple Instance Learning. (Pathology Research and Practice) This content is informational

13-year NordICC trial data

Skip to content The CRC Digest ▪ SCREENING 13-year NordICC trial data (Gastroenterology) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients

Skip to content The CRC Digest KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients A retrospective study investigated the distribution of specific KRAS mutation sites and their associations with clinicopathological parameters and survival outcomes. (Zhong Nan Da Xue Xue Bao Yi Xue Ban) This content is informational only

Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer Analysis of the Indiana Cancer Registry found that patients with dementia and stage I-III colorectal cancer have increased mortality and receive less invasive evaluations and surgery, with surgery

Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery

Skip to content The CRC Digest ▸ TREATMENT Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery A multicenter study of 3,385 rectal cancer patients aimed to compare short-term recovery, 6-month functional outcomes, and long-term survival among natural orifice specimen extraction surgery, laparoscopic surgery, and open surgery. (Diseases of

ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer Comprehensive genomic profiling of 56,206 advanced colorectal tumors characterized the prevalence and therapeutic implications of ALK fusions, which are established targets in lung cancer but rare in CRC. (The Oncologist) This

COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer A new analysis examines what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. (Journal of Clinical Oncology)